Intermittent preventive treatment for malaria in papua new guinean infants exposed to plasmodium falciparum and P. vivax: A randomized controlled trial

PLoS Medicine

Volumn 9, Issue 3, 2012, Pages

  Senn, Nicolas ^a,b,c,d   Rarau, Patricia ^a   Stanisic, Danielle I ^a,e   Robinson, Leanne ^a,e   Barnadas, Céline ^a,e   Manong, Doris ^a   Salib, Mary ^a   Iga, Jonah ^a   Tarongka, Nandao ^a   Ley, Serej ^a   Rosanas Urgell, Anna ^a   Aponte, John J ^f   Zimmerman, Peter A ^g   Beeson, James G ^e,h   Schofield, Louis ^e   Siba, Peter ^a   Rogerson, Stephen J ^b   Reeder, John C ^h   Mueller, Ivo ^a,e,f  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ANEMIA; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; MICROSCOPY; MULTICENTER STUDY; PAPUA NEW GUINEA; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; NEWBORN; PARASITOLOGY; PATHOGENICITY;

AMODIAQUINE; ANTIMALARIALS; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA; MALE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PYRIMETHAMINE; SULFADOXINE;

EID: 84858951938     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001195     Document Type: Article

References (57)

1. World Health Organization (2010) Guidelines for the treatment of malaria Geneva World Health Organization.
2. Lengeler C, (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004: CD000363.
3. Pluess B, Tanser FC, Lengeler C, Sharp BL, (2010) Indoor residual spraying for preventing malaria. Cochrane Database Syst Rev 2010: CD006657.
4. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009: CD007483.
5. Greenwood B, (2004) The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 70: 1-7.
6. Gosling R, Cairns M, Chico R, Chandramohan D, (2010 May) Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8: 589-606.
7. Menendez C, D'Alessandro U, ter Kuile FO, (2007) Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7: 126-135.
8. Crawley J, Hill J, Yartey J, Robalo M, Serufilira A, et al. (2007) From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis 7: 145-155.
9. Garner P, Gülmezoglu A, (2006) Drugs for preventing malaria-related illness in pregnant women. Cochrane Database Syst Rev 2006: CD000169.
10. Aponte J, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
11. Meremikwu MM, Donegan S, Esu E, (2008) Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database Syst Rev 2008: CD003756.
12. Institute of Medicine of the National Academies (2008) Assessment of the role of intermittent preventive treatment for malaria in infants: letter report Washington (District of Columbia) Institute of Medicine of the National Academies.
13. Wilson AL, on behalf of the IPTc Taskforce (2011) A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE 6: e16976 doi:10.1371/journal.pone.0016976.
14. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, et al. (2010) Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE 5: e12618 doi:10.1371/journal.pone.0012618.
15. Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, et al. (2008) Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 197: 1737-1742.
16. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1521-1532.
17. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, et al. (2009) High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS ONE 4: e4569 doi:10.1371/journal.pone.0004569.
18. World Health Organization (2010) WHO policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa Geneva World Health Organization.
19. Rosenberg R, (2007) Plasmodium vivax in Africa: hidden in plain sight? Trends Parasitol 23: 193-196.
20. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, et al. (2008) Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5: e127 doi:10.1371/journal.pmed.0050127.
21. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, et al. (2010) Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS ONE 5: e9047 doi:10.1371/journal.pone.0009047.
22. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128 doi:10.1371/journal.pmed.0050128.
23. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, et al. (2010) Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis 16: 1611-1614.
24. Lautze J, McCartney M, Krishen P, Olana D, Jayasinghe G, et al. (2007) Effect of a large dam on malaria risk: the Koka reservoir in Ethiopia. Trop Med Int Health 12: 982-989.
25. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555-566.
26. Hawkins VN, Suzuki SM, Rungsihirunrat K, Hapuarachchi HC, Maestre A, et al. (2009) Assessment of the origins and spread of putative resistance-conferring mutations in Plasmodium vivax dihydropteroate synthase. Am J Trop Med Hyg 81: 348-355.
27. Cattani JA, (1992) The epidemiology of malaria in Papua New Guinea. In: Attenborough R, Alpers M, editors. Human biology in Papua New Guinea: the small cosmos Oxford Clarendon Press pp. 302-312.
28. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, et al. (2010) Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J 9: 336.
29. Schellenberg D, Cisse B, Menendez C, (2006) The IPTi Consortium: research for policy and action. Trends Parasitol 22: 296-300.
30. Reed RB, Suart HC, (1959) Patterns of growth in height and weight from birth to eighteen years of age. Pediatrics 24: 904-921.
31. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA, (2004) Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by four human malaria parasite species. J Clin Microbol 42: 2403-2410.
32. Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, et al. (2006) Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg 75: 588-596.
33. Muller I, Genton B, Rare L, Kiniboro B, Kastens W, et al. (2009) Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J 8: 158.
34. Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, et al. (2010) Intermittent preventive treatment in infants for the prevention of malaria in rural western Kenya: a randomized, double-blind placebo-controlled trial. PLoS ONE 5: e10016 doi:10.1371/journal.pone.0010016.
35. May J, Adjei S, Busch W, Gabor J, Issifou S, et al. (2008) Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J 7: 198.
36. Krotoski WA, (1989) The hypnozoite and malarial relapse. Prog Clin Parasitol 1: 1-19.
37. Craige B, Alving AS, Jones R, Merrill Whorton C, Pullman TN, et al. (1947) The Chesson strain of Plasmodium vivax malaria: II. Relationship between prepatent period, latent period and relapse rate. J Infect Dis 80: 228-236.
38. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545-2557.
39. Marfurt J, Mueller I, Sie A, Maku P, Goroti M, et al. (2007) Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 77: 947-954.
40. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, et al. (2009) Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 199: 1074-1080.
41. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TME, et al. (2011) Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother 55: 4479-4481.
42. Picot S, Olliaro P, de Monbrison F, Bienvenu A, Price RN, et al. (2009) A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria J 8: 89.
43. Marfurt J, de Monbrison F, Brega S, Barbollat L, Muller I, et al. (2008) Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis 198: 409-417.
44. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, (2007) Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 23: 213-222.
45. Wong RP, Karunajeewa H, Mueller I, Siba P, Zimmerman PA, et al. (2011) Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob Agents Chemother 55: 798-805.
46. Rieckmann KH, Davis DR, Hutton DC, (1989) Plasmodium vivax resistance to chloroquine? Lancet 2: 1183-1184.
47. Muller I, Bockarie M, Alpers M, Smith T, (2003) The epidemiology of malaria in Papua New Guinea. Trends Parasitol 19: 253-259.
48. Mehlotra RK, Fujioka H, Roepe PD, Janneh O, Ursos LM, et al. (2001) Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci U S A 98: 12689-12694.
49. Karunajeewa HA, Ilett KF, Dufall K, Kemiki A, Bockarie M, et al. (2004) Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother 48: 2966-2972.
50. Salman S, Kose K, Griffin S, Baiwog F, Winmai J, et al. (2011) The pharmacokinetic properties of standard and double-dose sulfadoxine-pyrimethamine in infants. Antimicrob Agents Chemother 55: 1693-1700.
51. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, et al. (2009) Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 8: 200.
52. White NJ, (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3 doi:10.1371/journal.pmed.0020003.
53. Armstrong Schellenberg JRM, Shirima K, Maokola W, Manzi F, Mrisho M, et al. (2010) Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania. Am J Trop Med Hyg 82: 772-781.
54. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, et al. (2010) Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 54: 52-59.
55. Pell C, Straus L, Phuanukoonnon S, Lupiwa S, Mueller I, et al. (2010) Community response to intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea. Malar J 9: 369.
56. Ross A, Maire N, Sicuri E, Smith T, Conteh L, (2011) Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLoS ONE 6: e18391 doi:10.1371/journal.pone.0018391.
57. Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, et al. (2010) The cost-effectiveness of intermittent preventive treatment for malaria in infants in sub-Saharan Africa. PLoS ONE 5: e10313 doi:10.1371/journal.pone.0010313.